Alnylam Pharma (ALNY) Tops Q3 EPS by 43c, Misses on Revenue; Offers FY24 Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/3/2026

1. CRWD
2. AAPL
3. LITE
4. PLTR
5. REGN
6. ABBV
7. MRVL
8. CL
9. CHKP
10. LYB

Go back to Alnylam Pharma (ALNY) Tops Q3 EPS by 43c, Misses on Revenue; Offers FY24 Guidance

Alnylam Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Period Activity

October 31, 2024 8:00 AM EDT

Achieved Third Quarter 2024 Global Net Product Revenues of $420 Million, Representing 34% Year-Over-Year Growth Compared to Q3 2023, Driven by Continued Momentum from TTR Business

Submitted Regulatory Applications in U.S. and EU for AMVUTTRA® (vutrisiran) for the Treatment of Transthyretin Amyloidosis with Cardiomyopathy

Reiterated 2024 Financial Guidance, Including Combined Net Product Revenues of $1,575 Million to $1,650 Million

CAMBRIDGE, Mass.--(BUSINESS... More